(Au-Yeung et al., 2017) More than 20 CDK inhibitors exist and have been tested on CCNE1 amplified ovarian cancer cell lines with inconsistent efficacy and proposed resistance mechanisms including an increase in pro-survival signaling. The gene discussed is CCNE1; the disease is ovarian carcinoma.